Evaluation of efficacy of urinary uric acid excretion and urolithiasis related factor in urolithiasis patients with hyperuricemia by combination therapies of "Feburic tablets" and "Uralyt".
- Conditions
- rolithiasis patients with hyperuricemia
- Registration Number
- JPRN-UMIN000008752
- Lead Sponsor
- Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 40
Not provided
1) The patient who is developing gouty arthritis at the time of an eligibility judging, or has not passed two weeks since a gout arthritis disappearance day. 2) The patient who has not passed two weeks since the last medication day of the following combined use prohibition medicine at the time of an eligibility judging. Combined use prohibition drug of "Febric tablets". Mercaptopurine hydrate Azathioprine Combined use prohibition drug of "Uralyt". Hexamine mandelate 3) Serum creatinine level is more than 1.5 mg/dl. 4) Liver disease patients (either AST or ALT exceeds the twice of a standard value maximum). 5) Patients with severe cardiac disease, renal failure and other critical diseases. 6) Patients with drug allergy. 7) Patients who are considered to be inappropriate by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of the clinical laboratory test result in four weeks of study, and the degree of super saturation of a calcium oxalate or calcium phosphate.
- Secondary Outcome Measures
Name Time Method